Skip to content

Arvinas ARVN Long-Term Debt

Long-Term Debt at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$174.99M+77.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$100M+108%
Nuvation Bio logo
Nuvation BioNUVB
$47.33M
Merck & Co. logo
Merck & Co.MRK
$49.1B+41.1%
uniQure logo
uniQureQURE
$49.94M-3.2%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's long-term debt?
Arvinas (ARVN) reported long-term debt of $300K in Q1 2026.
How has Arvinas's long-term debt changed year-over-year?
Arvinas's long-term debt decreased by 40.0% year-over-year, from $500K to $300K.
What is the long-term trend for Arvinas's long-term debt?
Over 5 years (2020 to 2025), Arvinas's long-term debt has grown at a -27.5% compound annual growth rate (CAGR), from $2M to $400K.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.